Related MeSH Hierarchy (5)
Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Urogenital Neoplasms » Genital Neoplasms, Female » Fallopian Tube Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Genital Diseases, Female » Adnexal Diseases » Fallopian Tube Diseases » Fallopian Tube Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Urogenital Neoplasms » Genital Neoplasms, Female » Fallopian Tube Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Genital Diseases » Genital Diseases, Female » Adnexal Diseases » Fallopian Tube Diseases » Fallopian Tube Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Urogenital Neoplasms » Genital Neoplasms, Female » Fallopian Tube Neoplasms
Description
Benign or malignant neoplasms of the FALLOPIAN TUBES. They are uncommon. If they develop, they may be located in the wall or within the lumen as a growth attached to the wall by a stalk. MeSH
Hierarchy View
Approved Indicated Drugs (2)
Phase 4 Indicated Drugs (1)
Phase 3 Indicated Drugs (44)
Phase 2 Indicated Drugs (154)
modified vaccinia ankara-5t4 vaccine
modified vaccinia virus ankara vaccine expressing p53
oncolytic measles virus encoding thyroidal sodium iodide symporter
peg-pei-cholesterol lipopolymer-encased il-12 dna plasmid vector gen-1
Phase 1 Indicated Drugs (80)
ex vivo cd3/cd28-costimulated vaccine-primed peripheral blood autologous t cells
genetically engineered ny-eso-1-specific t lymphocytes
her2bi-armed activated t cells
Other Experimental Indicated Drugs (14)
Organization Involved with Phase 3 Indications (94)
Arbeitsgemeinschaft Gynaekologische Onkologie Austria
Australia New Zealand Gynaecological Oncology Group
Boryung Pharmaceutical Company
British Columbia Cancer Agency
Case Western Reserve University
Charité University, Berlin, Germany
European Network for Gynaecological Oncological Trial Groups
European Organisation for Research and Treatment of Cancer
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Grupo Español de Investigación en Cáncer de Ovario
Gynecologic Oncology Trial & Investigation Consortium
Huazhong University of Science and Technology
Katholieke Universiteit Leuven
National Cancer Institute (NCI)
Nordic Society for Gynaecologic Oncology
North Eastern Germany Society of Gynaecologic Oncology
OncoQuest Pharmaceuticals Inc.
People's Liberation Army of China
Royal College of Obstetricians and Gynecologists
Organization Involved with Phase 2 Indications (123)
Herbert Irving Comprehensive Cancer Center
ImmunoVaccine Technologies, Inc.
Jiangsu Cancer Institute & Hospital
KK Women's and Children's Hospital
Korean Gynecologic Oncology Group
Krankenhaus der Barmherzigen Schwestern Linz
Ludwig Institute for Cancer Research
Methodist Estabrook Cancer Center
National Institutes of Health (NIH)
National University of Singapore
New Mexico Cancer Care Alliance
Philipps University of Marburg
Shanghai Gynecologic Oncology Group
Shenzhen SiBiono GeneTech Co.,Ltd
Southeastern Gynecologic Oncology
State University of New York, Buffalo
The University of Texas, Dallas
Organization Involved with Phase 1 Indications (35)
Organization Involved with Other Experimental Indications (2)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.